GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lobe Sciences Ltd (OTCPK:LOBEF) » Definitions » Cyclically Adjusted Price-to-FCF

Lobe Sciences (Lobe Sciences) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Lobe Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lobe Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Lobe Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lobe Sciences Cyclically Adjusted Price-to-FCF Chart

Lobe Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Aug19 Aug20 Aug21 Aug22 Aug23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lobe Sciences Quarterly Data
Dec18 Mar19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 Aug23 Nov23 Feb24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lobe Sciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Lobe Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lobe Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lobe Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Lobe Sciences's Cyclically Adjusted Price-to-FCF falls into.



Lobe Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Lobe Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 is calculated as:

For example, Lobe Sciences's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2024 (Change)*Current CPI (Feb. 2024)
=-0/125.4675*125.4675
=0.000

Current CPI (Feb. 2024) = 125.4675.

Lobe Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201312 -0.082 96.945 -0.106
201403 -0.036 98.604 -0.046
201406 -0.043 99.473 -0.054
201409 -0.038 99.394 -0.048
201412 -0.023 98.367 -0.029
201503 -0.031 99.789 -0.039
201506 -0.014 100.500 -0.017
201509 -0.014 100.421 -0.017
201512 -0.007 99.947 -0.009
201603 -0.014 101.054 -0.017
201606 -0.014 102.002 -0.017
201609 -0.014 101.765 -0.017
201612 -0.006 101.449 -0.007
201703 -0.010 102.634 -0.012
201706 -0.016 103.029 -0.019
201709 -0.016 103.345 -0.019
201712 -0.013 103.345 -0.016
201803 -0.012 105.004 -0.014
201806 -0.008 105.557 -0.010
201809 -0.007 105.636 -0.008
201812 -0.001 105.399 -0.001
201903 -0.008 106.979 -0.009
201908 -0.064 108.085 -0.074
201911 -0.024 107.769 -0.028
202002 -0.014 108.559 -0.016
202005 -0.003 107.532 -0.004
202008 -0.029 108.243 -0.034
202011 -0.051 108.796 -0.059
202102 -0.047 109.745 -0.054
202105 -0.133 111.404 -0.150
202108 -0.018 112.668 -0.020
202111 -0.014 113.932 -0.015
202202 -0.017 115.986 -0.018
202205 -0.087 120.016 -0.091
202208 -0.011 120.569 -0.011
202211 -0.011 121.675 -0.011
202302 -0.006 122.070 -0.006
202308 0.000 125.389 0.000
202311 -0.001 125.468 -0.001
202402 0.000 125.468 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Lobe Sciences  (OTCPK:LOBEF) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Lobe Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Lobe Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Lobe Sciences (Lobe Sciences) Business Description

Industry
Traded in Other Exchanges
Address
1199 West Hastings Street, Suite 1400, Vancouver, BC, CAN, V6E 3T5
Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic stress disorder and devices for the efficient application of medications.